Citadel Advisors’s Cocrystal Pharma COCP Stock Holding History

Citadel Advisors’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,034	Closed	-$14.2K	–	12844
2025 Q1	$14.2K	Buy	+10,034	New	+$18.7K	﹤0.01%	13373
2022 Q4	–	Sell	-6,660	Closed	-$23K	–	14922
2022 Q3	$23K	Buy	+6,660	New	+$31.2K	﹤0.01%	12018
2021 Q4	–	Sell	-9,028	Closed	-$114K	–	13879
2021 Q3	$114K	Sell	9,028 -117	-1%	-$1.55K	﹤0.01%	12702
2021 Q2	$137K	Buy	+9,145	New	+$139K	﹤0.01%	12593
2020 Q2	–	Sell	-2,406	Closed	-$21K	–	9849
2020 Q1	$21K	Sell	2,406 -544	-18%	-$5.12K	﹤0.01%	9284
2019 Q4	$18K	Buy	+2,950	New	+$29.5K	﹤0.01%	8951
2019 Q3	–	Sell	-1,264	Closed	-$36K	–	9218
2019 Q2	$36K	Buy	1,264 +30	+2%	+$891	﹤0.01%	8824
2019 Q1	$40K	Buy	+1,234	New	+$45.2K	﹤0.01%	8902

Other funds holding COCP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's COCP Position: Q2 2025 in Review

Citadel Advisors sold out of Cocrystal Pharma (COCP) in Q2 2025, closing a stake of 10,034 shares — an estimated $14.2K sold.

Citadel Advisors first reported a position in COCP in Q1 2019 and held it in 8 quarters. The position peaked at $137K in Q2 2021. 22 funds tracked by Wall St. Rank hold COCP as of Q2 2025.

Citadel Advisors reported no remaining Cocrystal Pharma position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 10,034 Cocrystal Pharma shares in Q2 2025, an estimated $14.2K.
Citadel Advisors first reported a position in Cocrystal Pharma in Q1 2019 and held it in 8 quarters.
Citadel Advisors's Cocrystal Pharma position peaked at $137K in Q2 2021.
22 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.